SYMBIO PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 175 JPY | -1.69% |
|
-2.23% | -29.15% |
| Sales 2022 | 10.01B 63.43M | Sales 2023 | 5.59B 35.42M | Capitalization | 10.42B 66.05M |
|---|---|---|---|---|---|
| Net income 2022 | 1.18B 7.47M | Net income 2023 | -1.96B -12.44M | EV / Sales 2022 | 1.91 x |
| Net cash position 2022 | 6.28B 39.82M | Net cash position 2023 | 6.52B 41.3M | EV / Sales 2023 | 0.7 x |
| P/E ratio 2022 |
21.6
x | P/E ratio 2023 |
-5.02
x | Employees | 109 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.69% | ||
| 1 week | -2.23% | ||
| Current month | -5.41% | ||
| 1 month | -8.85% | ||
| 3 months | -23.25% | ||
| 6 months | -43.00% | ||
| Current year | -29.15% |
1 week
173.00
181.00
1 month
173.00191.00
Current year
173.00255.00
1 year
173.00483.00
3 years
173.002 566.00
5 years
173.002 566.00
10 years
173.002 566.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fuminori Yoshida
FOU | Founder | 75 | 05-03-24 |
| Director of Finance/CFO | - | - | |
| Chief Tech/Sci/R&D Officer | - | 23-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fuminori Yoshida
FOU | Founder | 75 | 05-03-24 |
| Director/Board Member | 78 | 19-02-28 | |
| Director/Board Member | 74 | 17-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 175 | -1.69% | 164 600 |
| 24-04-25 | 178 | -1.11% | 117,600 |
| 24-04-24 | 180 | 0.00% | 163,400 |
| 24-04-23 | 180 | +0.56% | 108,100 |
| 24-04-22 | 179 | +2.87% | 219,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.15% | 52.42M | |
| +26.30% | 653B | |
| +27.00% | 556B | |
| -6.71% | 354B | |
| +20.52% | 331B | |
| +2.16% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.20% | 144B |
- Stock Market
- Equities
- 4582 Stock
